Abstract 3917
Background
Delays in the initiation of therapy among patients with early stage and locally advanced breast cancer (BC), can negatively impact survival. Patients treated with neoadjuvant systemic chemotherapy (NSC) usually display tumors with high-risk features. Considering these high-risk characteristics, and the evidence supporting adverse outcomes associated with delays in adjuvant chemotherapy initiation, we sought to determine whether time to NSC is associated with survival outcomes.
Methods
We identified patients diagnosed with invasive primary BC (stage I–III)be tween January 1995-December 2015. All patients were treated with NSC at MD Anderson Cancer Center. Patients were categorized according to their time from BC diagnosis to NSC (in days) into one of the three subgroups: 0-30, 31–60, and 61 days. Primary endpoint was overall survival (OS). Descriptive statistics and Cox Proportional Hazard models were used.
Results
A total of5,137 patients were included. Median follow-up was 6.9 years. The 5-year OS estimates according to time to NSC were 87%, 85% and 83% in patients who received NSC within 0-30, 31-60 and 61 days after diagnosis, respectively (P = 0.006). In multivariable analysis, compared to time to NSC of 0-30 days, delayed NSC 61 days was associated with an increased risk of death (31-60 days HR = 1.05 [95%CI 0.92-1.19]; >61 days, HR = 1.28 [95%CI 1.06-1.54]). In stratified analyses, the association between delay in NSC initiation and increased risk of death was statistically significant for patients with stage I, II (31-60 days: HR = 1.22 [95%CI 1.02-1.47]; 61 days, HR = 1.41 [95%CI 1.07-1.86]) BC and among patients with HER2+ tumors (61 days, HR=1.86 [95%CI 1.21-2.86]).
Conclusions
A delay in NSC initiation of more than 61 days after BC diagnosis is associated with an increased risk of death. Early initiation of NSC should be a priority; multidisciplinary teams must focus in coordination of care and patient-centered timely treatment planning and delivery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
MD Anderson Cancer Center, Susan G Komen.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1837 - Oncological impact of re-excision for positive margin status after breast conserving surgery in invasive breast cancer
Presenter: Kenjiro Jimbo
Session: Poster Display session 2
Resources:
Abstract
4347 - Pneumonitis and fibrosis after breast cancer radiation.
Presenter: Jarle Karlsen
Session: Poster Display session 2
Resources:
Abstract
2280 - Prognosis of mastectomy with reconstruction after neoadjuvant chemotherapy: a nationwide study in Korean Breast Cancer Society
Presenter: Sungmin Park
Session: Poster Display session 2
Resources:
Abstract
804 - A negative prognosis of radiotherapy-induced lower lymphocyte to monocyte ratio in patients with breast cancer
Presenter: Chang-ik Yoon
Session: Poster Display session 2
Resources:
Abstract
2701 - Patient data to monitor clinical patterns in early and advanced breast cancer in Europe
Presenter: Francesco Giusti
Session: Poster Display session 2
Resources:
Abstract
1437 - A critical appraisal of quality indicators of breast cancer treatment in Belgium
Presenter: Didier Verhoeven
Session: Poster Display session 2
Resources:
Abstract
1534 - Predictors of adherence among post-menopausal women receiving adjuvant endocrine therapy for breast cancer in Ontario, Canada
Presenter: Phillip Blanchette
Session: Poster Display session 2
Resources:
Abstract
4363 - Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study
Presenter: Emilia Montagna
Session: Poster Display session 2
Resources:
Abstract
2679 - Baseline Quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): the French multicentric prospective CANTO cohort study
Presenter: Idlir Licaj
Session: Poster Display session 2
Resources:
Abstract
2840 - Effects of Aerobic and Resistance Exercise on Android:Gynoid Fat Ratio in Breast Cancer Survivors
Presenter: Christina Dieli-Conwright
Session: Poster Display session 2
Resources:
Abstract